Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 2/2016

01-02-2016 | Arrhythmia (D Spragg, Section Editor)

The Emerging Roles of Leadless Devices

Authors: Jeffrey Arkles, MD, Joshua Cooper, MD

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 2/2016

Login to get access

Opinion statement

The role of leadless devices to treat cardiac rhythm disorders and heart failure is emerging. Subcutaneous defibrillator (S-ICD) and leadless pacemakers were developed to ameliorate the risks associated with chronic transvenous leads. Potential benefits of leadless pacemakers and S-ICD include more favorable infection profile, less risk of venous stenosis or occlusion, and less risk of tricuspid valve insufficiency. Novel implantable leadless monitors for heart failure represent a novel diagnostic tool that can guide therapy for CHF.
Literature
1.
Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474–80.CrossRefPubMed
2.
Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12.PubMed
3.
Hreybe H, Razak E, Saba S. Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. PACE - Pacing Clin Electrophysiol. 2007;30:1091–5.CrossRefPubMed
4.
Luedemann M, Hund K, Stertmann W, Michel-Behnke I, Gonzales M, Akintuerk H, et al. Implantable cardioverter defibrillator in a child using a single subcutaneous array lead and an abdominal active can. PACE - Pacing Clin Electrophysiol. 2004;27:117–9.CrossRefPubMed
5.
Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol. 2011;58:889–96.CrossRefPubMed
6.
Baquero GA, Luck J, Naccarelli GV, Gonzalez MD, Banchs JE. Tricuspid valve incompetence following implantation of ventricular leads. Curr Heart Fail Rep. 2015;12:150–7.CrossRefPubMed
7.
Supple GE, Ren J-F, Zado ES, Marchlinski FE. Mobile thrombus on device leads in patients undergoing ablation: identification, incidence, location, and association with increased pulmonary artery systolic pressure. Circulation. 2011;124:772–8.CrossRefPubMed
8.
Wazni O, Epstein LM, Carrillo RG, Love C, Adler SW, Riggio DW, et al. Lead extraction in the contemporary setting: the LExICon Study. An observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol. 2010;55:579–86.CrossRefPubMed
9.
Knops RE, Olde Nordkamp LR, De Groot JR, Wilde AA. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Hear Rhythm. 2013;10:1240–3.CrossRef
10.
Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36–44. Novel.CrossRefPubMed
11.
Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944–53.CrossRefPubMed
12.
Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, Maass AH, De Groot JR, Van Oostrom AJHHM, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60:1933–9.CrossRefPubMed
13.
Jarman JWE, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace. 2013;15:1158–65.CrossRefPubMed
14.
Jarman JWE, Lascelles K, Wong T, Markides V, Clague JR, Till J. Clinical experience of entirely subcutaneous implantable cardioverterdefibrillators in children and adults: cause for caution. Eur Heart J. 2012;33:1351–9.CrossRefPubMed
15.
Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Rosenmöller BRAM, Wilde AAM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25:494–9.CrossRefPubMed
16.•
Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA M, De Groot JR. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. Hear Rhythm. 2014;11:426–34. Method to improve sensing using the S-ICD.CrossRef
17.
Lambiase PD, Barr C, Theuns DAMJ, Knops R, Neuzil P, Johansen JB, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry. Eur Heart J. 2014;35:1657–65.PubMedCentralCrossRefPubMed
18.
Acha MR, Milan D. Timing is not right to replace the transvenous implantable cardioverter defibrillator. Circ Arrhythmia Electrophysiol. 2013;6:1246–51.CrossRef
19.
Spickler JW, Rasor NS, Kezdi P, Misra SN, Robins KE, LeBoeuf C. Totally self-contained intracardiac pacemaker. J Electrocardiol. 1970;3:325–31.CrossRefPubMed
20.•
Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129:1466–71. Novel description of a leadless pacemaker in man.CrossRefPubMed
21.•
Ritter P, Duray GZ, Steinwender C, Soejima K, Omar R, Mont L, et al, Micra Transcatheter Pacing Study Group. Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. Eur Heart J. 2015. First experience with the Medtronic Micra leadless pacemaker.
22.
Adamson PB, Magalski A, Braunschweig F, Böhm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–71.CrossRefPubMed
23.••
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66. First trial showing benefit for leadless pulmonary artery pressure monitor.CrossRefPubMed
Metadata
Title
The Emerging Roles of Leadless Devices
Authors
Jeffrey Arkles, MD
Joshua Cooper, MD
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 2/2016
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-015-0424-8

Other articles of this Issue 2/2016

Current Treatment Options in Cardiovascular Medicine 2/2016 Go to the issue

Heart Failure (W Tang, Section Editor)

Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Management of Coronary Artery Disease and Conduction Abnormalities in Transcatheter Aortic Valve Implantation

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

Glycemic Control in Coronary Revascularization

Heart Failure (W Tang, Section Editor)

Management of Cardio-Renal Syndrome and Diuretic Resistance

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)

In-Stent Restenosis: Pathophysiology and Treatment

Heart Failure (W Tang, Section Editor)

Desensitization Strategies Pre- and Post-Cardiac Transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits